Eli Lilly to Invest $1 Billion in Hyderabad Contract Manufacturing and Oversight Facility

U.S.-based pharmaceutical major Eli Lilly and Company has announced plans to invest over $1 billion in India, establishing a new contract manufacturing and oversight facility in Hyderabad. The investment, one of the largest pharma commitments in recent years, aims to expand the company’s manufacturing and global medicine supply capacity while generating significant employment opportunities in Telangana.

Strengthening India’s Pharma Hub

The new facility will serve as a technical and quality oversight hub for Lilly’s contract manufacturing network across India, marking a major boost to Hyderabad’s growing status as a global healthcare innovation center. Telangana Chief Minister A. Revanth Reddy and Industries Minister D. Sridhar Babu met with Eli Lilly leadership to finalize the proposal. The State government highlighted that the investment reflects growing investor confidence in Telangana’s industry-friendly policies and life sciences ecosystem.

Global Expansion and Local Impact
Eli Lilly’s Executive Vice President Patrik Jonsson emphasized that the investment aligns with the company’s global capacity expansion strategy and India’s Make in India initiative. Since 2020, Lilly has committed over $55 billion globally to expand its manufacturing footprint, supporting future medicines for diabetes, obesity, Alzheimer’s, cancer, and autoimmune diseases. The Hyderabad facility will immediately begin hiring engineers, chemists, analytical scientists, and quality professionals, strengthening India’s role in the global pharmaceutical supply chain.